Search Results
Oct 22, 2025, 08:07 ET CND Life Sciences Announces NIH Grant to Study the Risk of Parkinson's Disease in Patients with Essential Tremor
multicenter study is to determine whether individuals diagnosed with ET have P-SYN, the misfolded protein that is linked to PD, and whether this protein increases the risk of PD development. ET is an involuntary rhythmic shaking, most often seen in a person's hands, arms, legs, and head, which can impact
More news about: CND Life Sciences
Oct 21, 2025, 20:25 ET Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
IBI363 (PD-1/IL-2α-bias): Global Joint Development and Commercialization Collaboration IBI363, developed by Innovent Biologics, is a potentially first-in-class PD-1/IL-2α-biased bispecific antibody fusion
More news about: Innovent Biologics
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more
More news about: Astellas Pharma Inc.
Oct 21, 2025, 11:50 ET Pioneering Physician-Scientist Dr. Francis S. Collins Joins ImmunoBrain Board of Directors
plays a key role in brain aging and neurodegenerative diseases. These discoveries led to the development of IBC-Ab002, a proprietary Fc-modified anti-PD-L1 antibody, designed and optimized by ImmunoBrain for the treatment of neurological diseases, based on the understanding of its mechanism of action
More news about: ImmunoBrain Checkpoint Inc.
Oct 21, 2025, 10:06 ET KOSPET Launches TANK T4 & M4: Flagship Outdoor Adventure Smartwatches
no-decompression time. Wellness suite & next-gen sensor: Advanced 4PD optical sensor for improved HRV/stress/sleep accuracy; emotion tracking, menstrual tracking, one-tap health.
More news about: KOSPET
Oct 21, 2025, 07:00 ET HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs
More news about: HanchorBio Inc.
Oct 21, 2025, 01:37 ET Headwolf Titan 1 -- 8.8" Gaming Tablet Built for Power
Power: 7200mAh Battery + PD Fast Charging A gaming tablet is only as good as its battery— and the Titan 1's 7200mAh cell delivers all-day playtime (enough for 6+ hours of Genshin Impact). When you need to replenish your battery, the PD fast charging technology
More news about: HEADWOLF
Oct 20, 2025, 17:31 ET Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
perioperative radiotherapy remain uncertain. Immunotherapy has shown promising results in certain studies, particularly in patients with elevated PD-L1 and PD-L2 expression. Future research is expected to explore immunotherapy mechanisms in greater depth and identify more precise prognostic markers, enabling
More news about: DelveInsight Business Research, LLP
Oct 20, 2025, 12:30 ET iVANKY Introduces FusionDock Max 2: The First MacBook Dock for Thunderbolt 5 with Native Triple-Display Support
once. Alongside speed and display power, the dock delivers reliable charging with 140 W for MacBook and an independent 30 W USB-C PD port for accessories. Its 23 ports cover every professional need, from 2.5G Ethernet and SD 4.0 to optical audio and multiple 10 Gbps USB connections.
More news about: iVANKY
Oct 20, 2025, 09:31 ET Yale Faculty Recognized with Prestigious National Honors for Achievements in Health and Medicine
our understanding of how cancers evade immune detection. Chen discovered the PD-L1 molecule, a protein expressed on cancer cells that suppresses the immune response and promotes tumor growth. His work also revealed that PD-L1 is highly upregulated in some cancers and that targeting the molecule can help
More news about: Yale School of Medicine
Oct 20, 2025, 09:31 ET 耶魯大學教職員榮獲國家級殊榮，表彰其在健康與醫學領域的卓越成就
Lieping Chen，醫學博士、哲學博士，United Technologies Corporation 癌症研究講座教授，同時擔任免疫生物學、皮膚科及內科學（醫學腫瘤學）教授，因其在深化人類對癌症如何逃避免疫偵測機制的基礎貢獻，獲選為美國國家醫學院院士。Chen 博士發現了 PD-L1 分子——一種表達於癌細胞表面的蛋白質，能抑制免疫反應並促進腫瘤生長。他的研究還揭示，PD-L1 在某些癌症中會高度上調，且針對該分子進行治療有助於免疫系統清除腫瘤，為關鍵免疫療法奠定了基礎。
More news about: Yale School of Medicine
Oct 20, 2025, 09:31 ET Facultad de Yale reconocida con prestigiosos honores nacionales por sus logros en salud y medicina
cómo los cánceres evaden la detección inmune. Chen descubrió la molécula PD-L1, una proteína expresada en las células cancerosas que suprime la respuesta inmune y promueve el crecimiento tumoral. Su trabajo también reveló que PD-L1 está altamente regulado al alza en algunos cánceres y que dirigirse a
More news about: Yale School of Medicine
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
poster presentation from HCB301, revealing the first-time the preclinical data from HanchorBio's novel tri-specific fusion protein targeting CD47-SIRPα, PD-1, and TGFb pathways ESMO Asia Congress, December 5-7, 2025– One abstract updating the results from HCB101-101, demonstrating
More news about: HanchorBio Inc.
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
offers limited overall benefit. In recent years, regimens of chemotherapy plus immune checkpoint inhibitors+anti-angiogenic agents, or EGFR/c-Met bsAb, or PD-1/VEGF bsAb, have been successively approved for this indication. However, all these approaches are chemotherapy-based, highlighting an urgent need to
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
Pembrolizumab is a monoclonal antibody drug known as a PD-1 inhibitor. The drug treats many kinds of cancer and works by blocking a protective mechanism, the PD-1 protein receptor, that cancer cells use to avoid detection by the body's immune system. Blocking PD-1 allows immune cells to recognize harmful cancer
More news about: NYU Langone Health System
Oct 20, 2025, 02:20 ET Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in
More news about: Hengrui Pharma
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). Antengene
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
clinical data publication of a PD-1/VEGF/CTLA-4 trispecific antibody to date. CS2009-101 is a multi-regional phase Ⅰ study currently ongoing in Australia and China. The study evaluates the safety, tolerability, pharmacokinetics (PK)/ pharmacodynamics (PD), and antitumor activity of
More news about: CStone Pharmaceuticals
Oct 19, 2025, 11:42 ET Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
In the COMPASSION-15 study, patients with PD-L1 CPS <5 (low expression) and CPS <1 (negative expression) are 49.8% and 23%, respectively, of the ITT population. This represents a higher proportion of PD-L1 low and negative patient population in COMPASSION-15 compared to
More news about: Akeso, Inc.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Consistent clinical benefits were observed across all PD-L1 expression subgroups. In the PD-L1 negative (TPS <1%) population, the PFS HR was 0.55 for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. In the PD-L1 positive (TPS ≥1%) population, the PFS HR was 0.66 for ivonescimab
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Patients with R/M HNSCC have limited options and poor outcomes after disease progression on a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy.2 Many are unable to receive further treatment, and for those who do, response rates with
More news about: Johnson & Johnson
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
recurrent or metastatic NPC patients who had progressed after at least two prior lines of chemotherapy, including platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. These results were presented today in a late-breaking oral presentation at the 2025 European Society of Medical Oncology (ESMO) Congress.
More news about: SystImmune, Inc.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
platinum-containing chemotherapy. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more
More news about: Astellas Pharma Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
dose-expansion cohort of E7386 + envatinib in patients with advanced/recurrent endometrial cancer that progressed on platinum-based chemotherapy and an anti−PD-(L)1 immunotherapy Bradley Monk, MD:Niraparib first-line maintenance therapy in patients with newly diagnosed
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
therapy tailored to each patient's unique tumor profile and immune characteristics, with the trial evaluating EVX-01 in combination with MSD's anti-PD-1 therapy KEYTRUDA. RenovoRx, Inc. (NASDAQ: RNXT) has successfully completed the
More news about: Equity Insider